About the Study

Welcome to the Solutions for Celiac website.


This NIH-funded clinical research study has been designed to assess the drink-based investigational medication latiglutenase and its ability to relieve common symptoms suffered by celiac disease patients after accidental gluten exposure in a real-world setting.  Latiglutenase consists of a combination of two enzymes which efficiently degrade gluten in the stomach when taken during meals.


Study Details

As a study participant, you will be required to attend up to six (6) in-person clinic visits over the course of 26 weeks.  In addition, you will be asked to complete a daily electronic symptoms diary.  You will be required to take either the investigational medication or placebo three times per day (breakfast, lunch and dinner) for 17 of the 26 weeks.  The placebo resembles the investigational medication, but does not contain the active ingredients.


Participants will receive all study supplies, including the investigational medication as well as all study-related tests and procedures at no cost.  Qualified participants may be reimbursed for study participation, including transportation costs. 


Please help advance a therapy for celiac patients by clicking the “See If You Pre-Qualify” button to learn more.  Should you pre-qualify for the study, a study staff member will contact you and share additional study details as well as answer any of your questions.         

For further information, refer to our study page on ClinicalTrials.gov.

Share information about the Solutions for Celiac Study

©2020 by ImmunogenX